PL355892A1 - 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor - Google Patents

4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor

Info

Publication number
PL355892A1
PL355892A1 PL00355892A PL35589200A PL355892A1 PL 355892 A1 PL355892 A1 PL 355892A1 PL 00355892 A PL00355892 A PL 00355892A PL 35589200 A PL35589200 A PL 35589200A PL 355892 A1 PL355892 A1 PL 355892A1
Authority
PL
Poland
Prior art keywords
carboxyamino
tetrahydroquinoline
ethyl
crystal
cetp inhibitor
Prior art date
Application number
PL00355892A
Other languages
English (en)
Polish (pl)
Inventor
Douglas John Meldrum Allen
Troy Anthony Appleton
Lyle Robinson Brostrom
Derek Lawrence Tickner
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL355892A1 publication Critical patent/PL355892A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
PL00355892A 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor PL355892A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30
PCT/IB2000/001650 WO2001040190A1 (fr) 1999-11-30 2000-11-14 Cristaux de 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoleine utilises en tant qu'inhibiteurs de cetp

Publications (1)

Publication Number Publication Date
PL355892A1 true PL355892A1 (en) 2004-05-31

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00355892A PL355892A1 (en) 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor

Country Status (28)

Country Link
EP (1) EP1246804A1 (fr)
JP (1) JP2003515592A (fr)
KR (1) KR20020058057A (fr)
CN (1) CN1402711A (fr)
AP (1) AP2002002531A0 (fr)
AU (1) AU1048801A (fr)
BG (1) BG106854A (fr)
BR (1) BR0015836A (fr)
CA (1) CA2392979A1 (fr)
CO (1) CO5271716A1 (fr)
EA (1) EA200200510A1 (fr)
EC (1) ECSP003792A (fr)
EE (1) EE200200277A (fr)
GT (1) GT200000199A (fr)
HU (1) HUP0203521A2 (fr)
IL (1) IL149097A0 (fr)
IS (1) IS6338A (fr)
MA (1) MA26845A1 (fr)
MX (1) MXPA02005354A (fr)
NO (1) NO20022558L (fr)
OA (1) OA12099A (fr)
PA (1) PA8506301A1 (fr)
PE (1) PE20010904A1 (fr)
PL (1) PL355892A1 (fr)
TN (1) TNSN00231A1 (fr)
TR (1) TR200201446T2 (fr)
UY (1) UY26454A1 (fr)
WO (1) WO2001040190A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
JP2005500314A (ja) * 2001-06-21 2005-01-06 ファイザー・プロダクツ・インク コレステロールエステル転送蛋白インヒビターの自己乳化性製剤
GT200200170A (es) * 2001-09-28 2003-05-23 Preparacion de inhibidor de cetp anhidro
EP1920766B1 (fr) * 2002-02-01 2017-08-23 Bend Research, Inc Compositions pharmaceutiques de dispersions amorphes de médicaments et matériaux formant des microphases lipophiles
EP1469832B2 (fr) 2002-02-01 2016-10-26 Bend Research, Inc. Compositions pharmaceutiques de dispersions amorphes de medicaments et materiaux formant des microphases lipophiles
CN1309370C (zh) * 2002-02-01 2007-04-11 辉瑞产品公司 使用改进的喷雾干燥设备制备均匀喷雾干燥的固体非晶形药物分散体的方法
CN1289467C (zh) 2002-08-30 2006-12-13 日本烟草产业株式会社 二苄胺化合物及其药物用途
AU2003277285B2 (en) 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
DE60331873D1 (de) 2002-12-20 2010-05-06 Pfizer Prod Inc Dosierungsform enthaltend einen CETP-Hemmer und einen HMG-CoA Reduktase Hemmer
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EA200501376A1 (ru) * 2003-03-28 2006-04-28 Пфайзер Продактс Инк. Производные 1,2,4-замещённых 1,2,3,4-тетрагидро- и 1,2-дигидрохинолинов и 1,2,3,4-тетрагидрохиноксалина в качестве ингибиторов сетр для лечения атеросклероза и тучности
CA2532931A1 (fr) 2003-08-04 2005-02-10 Pfizer Products Inc. Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles
MXPA06003927A (es) 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
EP1737811B1 (fr) * 2004-04-13 2016-08-10 Merck Sharp & Dohme Corp. Inhibiteurs de cetp
KR20070041452A (ko) * 2004-06-24 2007-04-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
WO2006033001A1 (fr) * 2004-09-23 2006-03-30 Pfizer Products Inc. Composes de quinoline
WO2006033004A1 (fr) * 2004-09-23 2006-03-30 Pfizer Products Inc. Composes de quinoline en tant qu'inhibiteurs de cetp
WO2006091674A1 (fr) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires
WO2006098394A1 (fr) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
EP3174995B1 (fr) 2014-07-30 2020-08-19 F.Hoffmann-La Roche Ag Marqueurs génétiques pour la prédiction de la réactivité à une thérapie avec un agent d'augmentation de hdl ou d'imitation de hdl

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
AU5731098A (en) * 1997-02-03 1998-08-25 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
WO2001040190A1 (fr) 2001-06-07
EE200200277A (et) 2003-10-15
AP2002002531A0 (en) 2002-06-30
OA12099A (en) 2006-05-04
MXPA02005354A (es) 2002-12-11
TR200201446T2 (tr) 2002-11-21
IL149097A0 (en) 2002-11-10
UY26454A1 (es) 2001-07-31
AU1048801A (en) 2001-06-12
EP1246804A1 (fr) 2002-10-09
NO20022558D0 (no) 2002-05-29
PE20010904A1 (es) 2001-09-10
KR20020058057A (ko) 2002-07-12
BR0015836A (pt) 2002-08-06
CA2392979A1 (fr) 2001-06-07
JP2003515592A (ja) 2003-05-07
GT200000199A (es) 2002-05-23
CN1402711A (zh) 2003-03-12
CO5271716A1 (es) 2003-04-30
NO20022558L (no) 2002-05-29
HUP0203521A2 (hu) 2003-02-28
ECSP003792A (es) 2002-04-23
PA8506301A1 (es) 2002-08-26
TNSN00231A1 (fr) 2002-05-30
EA200200510A1 (ru) 2002-10-31
IS6338A (is) 2002-04-12
MA26845A1 (fr) 2004-12-20
BG106854A (bg) 2002-12-29

Similar Documents

Publication Publication Date Title
PL355892A1 (en) 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor
IL173393A0 (en) 4-carboxyamino-2- substituted-1,2,3,4- tetrahydroquinolines as cetp inhibitors
SI1114033T1 (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors
PL346830A1 (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
MXPA01013406A (es) Compuestos inhibidores de vla-4.
ZA200203095B (en) Biphenyl derivatives used as NHE-3 inhibitors.
IL150114A0 (en) Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
HK1047596A1 (en) 14, 15-Beta-methylene substituted androgens
GB9914583D0 (en) Novel process
GB9916392D0 (en) Novel process
SI1114031T1 (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
GB9916187D0 (en) Novel process
GB9921243D0 (en) Novel process
CA88265S (en) Sunglasses
CA88270S (en) Sunglasses
CA88264S (en) Sunglasses
GB9904104D0 (en) Quinoline derivatives
GB9904102D0 (en) Quinoline derivatives
GB9904105D0 (en) Quinoline derivatives
ZA200109203B (en) VLA-4 inhibitor compounds.
AU137566S (en) Sunglasses
AU141767S (en) Sunglasses
AU141770S (en) Sunglasses
AU141769S (en) Sunglasses
AU141772S (en) Sunglasses

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)